Max Health is pleased to announce the upcoming launch of Clindamycin-hameln, 150mg/mL solution for injection, the newest addition to Hameln Pharma’s growing product portfolio in New Zealand.
Clindamycin Injection has been awarded Principal Supply Status from the 1st August 2023 and will be available in New Zealand from the 12th February 2023 from Onelink. This recent announcement is a testament to the commitment of Max Health and Hameln in serving the wellbeing of patients through supply of high quality and reliable European products in New Zealand.
Clindamycin details are as follows:
Name: Clindamycin Injection
Strength: 150mg/mL, 4mL x 10
Onelink Code: PHZB72
Pharmacode: 2646595
Price: POA
As with all other Max Health products, Clindamycin can be ordered from Onelink via the following details.
Phone: 0800 70 80 60
Fax: 0800 26 69 60
Email: customerservices@onelink.co.nz
About Hameln Plus – Germany
The Hameln group, based in Hameln Germany has over 100 years of company history behind it, having been run by the same family for four generations. It produces an outstanding range of injectable anaesthetic and intensive medicine products, in a state of the art sterile facility. Products approved and marketed in NZ include Alfentanil, Cyclizine, Dexamethasone, Amiodarone, Naloxone, Neostigmine, Oxycodone, Dobutamine, Flumazenil and Rocuronium injections.
About Max Health
Established in 2008, Max Health™ is a New Zealand founded pharmaceutical company providing products and solutions to the New Zealand health care market. We distribute a wide variety of pharmaceutical products sourced from well established European pharmaceutical companies. We pride ourselves in providing high quality products with reliable local service.
